

AMENDMENTS TO THE CLAIMS

The claims as listed below will replace all prior listings and presentations of claims in the above-identified application.

Please amend Claims 1, 4 and 48, and add new Claims 50-72 as follows:

1. **(Currently Amended)** An implant for treating an ocular disorder glaucoma, comprising:

a body comprising material that includes a therapeutic drug, said body having an inlet portion and an outlet portion, said inlet portion configured to reside in an [[the]] anterior chamber of an eye when the outlet portion is disposed in a physiological outflow pathway of the eye, said outlet portion having an outflow opening such that said body drains transports fluid from the anterior chamber to the physiological outflow pathway.

2. **(Previously Presented)** The implant of Claim 1, wherein said body is coated with said therapeutic drug.

3. **(Original)** The implant of Claim 1, wherein said drug comprises heparin.

4. **(Currently Amended)** An implant for treating an ocular disorder glaucoma, comprising:

a body having a therapeutic drug in or on said body, said body having an inlet portion and an outlet portion, said inlet portion configured to drain transmit fluid from an [[the]] anterior chamber of an eye to the outlet portion when the outlet portion is disposed in a physiological outflow pathway, said outlet portion having an outflow opening.

5. **(Previously presented)** The implant of Claim 4, wherein said body is coated with said therapeutic drug.

6. **(Previously Presented)** The implant of Claim 4, wherein said therapeutic drug comprises heparin.

7.-45. **(Canceled).**

46. **(Previously Presented)** The implant of Claim 1, wherein the physiological outflow pathway is Schlemm's canal.

47. **(Previously Presented)** The implant of Claim 4, wherein the physiological outflow pathway is Schlemm's canal.

48. (Currently Amended) A method of treating an ocular disorder glaucoma, comprising:

introducing an implant comprising a therapeutic drug into an [[the]] anterior chamber of an eye; and

advancing said implant into eye tissue adjacent the anterior chamber such that the implant drains aqueous humor from the anterior chamber into a physiological outflow pathway and the therapeutic drug reaches eye tissue ~~in which the implant is implanted.~~

49. (Previously Presented) The method of Claim 48, wherein the implant is coated with said therapeutic drug.

50. (New) The method of Claim 48, wherein advancing the implant into eye tissue involves positioning at least a portion of the implant so as to contact a choroid of the eye.

51. (New) The method of Claim 48, wherein advancing the implant into eye tissue involves positioning a distal end of the implant so as to drain aqueous humor toward a choroid of the eye.

52. (New) The implant of Claim 1, wherein the body includes a first portion and a second portion that is appended from the first portion, and wherein the first portion includes a lumen and the second portion carries the therapeutic drug.

53. (New) The implant of Claim 1, wherein the implant is substantially L-shaped.

54. (New) The implant of Claim 1, wherein the body has a sufficient length to extend from the anterior chamber into Schlemm's canal.

55. (New) The implant of Claim 4, wherein the body includes a first portion and a second portion that is appended from the first portion, and wherein the first portion includes a lumen and the second portion carries the therapeutic drug.

56. (New) The implant of Claim 4, wherein the implant comprises a protrusion configured to stabilize the implant in eye tissue.

57. (New) The implant of Claim 4, wherein the body has a sufficient length to extend from the anterior chamber into Schlemm's canal.

58. (New) A method of treating an ocular disorder, comprising:

introducing an implant comprising a therapeutic drug into an anterior chamber of an eye; and

advancing said implant into eye tissue such that the implant is in contact with at least a choroid of the eye.

59. (New) The method of Claim 58 additionally comprising draining aqueous humor from the anterior chamber into a physiologic outflow pathway through the implant.

60. (New) The method of Claim 58 additionally comprising controlling aqueous humor flow through a lumen of the implant.

61. (New) The method of Claim 58, wherein the implant includes a hollow filled with the therapeutic drug.

62. (New) The method of Claim 58, wherein the implant includes a first portion and a second portion that is appended from the first portion, the first portion including a lumen and the second portion carrying the therapeutic drug.

63. (New) The method of Claim 58, wherein the therapeutic drug comprises a compound of drugs, at least one of which is therapeutic.

64. (New) A method of treating an ocular disorder, comprising:
forming an incision in an eye;
inserting an implant through the incision into an anterior chamber of the eye, the implant comprising a therapeutic drug; and
inserting the implant into eye tissue such that the implant drains aqueous humor from the anterior chamber toward a choroid of the eye.

65. (New) The method of Claim 64 additionally comprising draining aqueous humor from the anterior chamber into a physiologic outflow pathway through the implant.

66. (New) The method of Claim 64, wherein the implant includes a first portion and a second portion that is appended from the first portion, the first portion including a lumen and the second portion carrying the therapeutic drug.

67. (New) A method of treating an ocular disorder, comprising:
placing an implant in contact with a choroid of an eye, said implant having at least one flow channel;
flowing a fluid, which comprises aqueous humor, along the flow channel of the implant; and
eluting a therapeutic agent from the implant.

68. (New) The method of Claim 67 additionally comprising advancing the implant through an anterior chamber of the eye toward an implantation site.
69. (New) The method of Claim 67 additionally comprising advancing the implant through scleral tissue of the eye toward an implantation site.
70. (New) A method of treating an ocular disorder, comprising:
 - providing an implant having at least one lumen extending between an inlet and an outlet, and at least one anchor projecting outwardly from the lumen;
 - using the anchor to retain the implant in eye tissue;
 - positioning the outlet in tissue so as to fluidically communicate directly with a physiologic outflow pathway; and
 - eluting a therapeutic agent from the implant.
71. (New) The method of Claim 70 additionally comprising advancing the implant through an anterior chamber of the eye toward an implantation site.
72. (New) The method of Claim 70 wherein the method further comprises advancing the implant through scleral tissue of the eye when positioning the outlet.